



Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQB: LVCLY

ASX ANNOUNCEMENT

Investor Webinar

Highlights

- **LCT invites investors to attend a webinar hosted by Executive Chairman, Professor Bernie Tuch, from 11am AEDT (1pm NZ time) Thursday, 10 March 2022**
- **Register to attend via this link:**
<https://attendee.gotowebinar.com/register/818493369818923024>

Sydney, Australia & Auckland, New Zealand - 4 March 2022 – Living Cell Technologies (ASX:LCT) invites investors to attend a webinar to be held from 11am AEDT (1pm New Zealand time) next Thursday, 10 March 2022.

The webinar will feature a presentation from LCT Executive Chairman, Professor Bernie Tuch on the company's activities including the third clinical trial of NTCELL in Parkinson's disease, together with its strategy for 2022.

Attendees may submit questions to the company prior to the event or during the webinar via the control panel. A recording will also be made available following the webinar via LCT's website and social media.

Webinar details

Time: 11am – 12pm AEDT (1pm NZ time) Thursday, 10 March 2022

RSVP: <https://register.gotowebinar.com/register/818493369818923024>

Dial-in numbers: Australia +61 2 9091 7604; New Zealand +64 4 974 7212

Access code for attendees: 624-953-609

For any questions concerning the webinar, please email anthony@republicpr.com.au or phone +61 (0)407 112 623.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company: Bernie Tuch Chief Executive Mobile: +61 411 461 604 bernietuch@lctglobal.com	For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au
---	---

About Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.